Dietmar Berger
CIK 1739515 · View on SEC EDGAR ↗
First SEC filing: Feb. 10, 2025 · Latest: June 11, 2026
On this page
- Insider at Companies where this person is a reporting insider.
- Insider transactions Every share this person bought or sold, from Form 4 filings.
- Derivatives Options and other derivative holdings reported by this person.
- Initial holdings The stakes this person held when they first started reporting.
- Compensation Executive pay disclosed in company proxy statements.
Insider at
Insider transactions
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
No open-market trades on record; showing all filings.
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| June 10, 2026 | GILD | F | 263 | $121.48 | $31,949 | 19,252 | — | — | 19.2% (price as of 2026-08-21) |
| June 10, 2026 | GILD | M | 533 | — | — | 19,252 | — | — | (price as of 2026-08-21) |
| March 10, 2025 | GILD | A | 37,710 | — | — | 37,710 Direct | — | Acquired | (price as of 2026-08-21) |
| March 10, 2025 | GILD | A | 8,530 | — | — | 57,505 Direct | +17.42% | Acquired | (price as of 2026-08-21) |
| Jan. 2, 2025 | GILD | A | 48,975 | — | — | 48,975 Direct | — | Acquired | (price as of 2026-08-21) |
| May 7, 2019 | ATRA | F | 4,322 | $33.46 | $144,614 | 85,678 Direct | -4.80% | Disposed | -98.9% (price as of 2026-08-21) |
| March 26, 2019 | ATRA | A | 15,000 | — | — | 90,000 Direct | +20.00% | Acquired | (price as of 2026-08-21) |
| Feb. 6, 2019 | ATRA | A | 50,000 | — | — | 50,000 Direct | — | Acquired | (price as of 2026-08-21) |
| Feb. 6, 2019 | ATRA | A | 25,000 | — | — | 75,000 Direct | +50.00% | Acquired | (price as of 2026-08-21) |
| May 7, 2018 | ATRA | A | 85,000 | — | — | 85,000 Direct | — | Acquired | (price as of 2026-08-21) |
| May 7, 2018 | ATRA | A | 50,000 | — | — | 50,000 Direct | — | Acquired | (price as of 2026-08-21) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II)
Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| March 10, 2025 | GILD | Non-qualified Stock Option (Right to Buy) | Common Stock (37,710) | $117.21 | March 10, 2035 | 37,710 | Acquired |
| March 10, 2025 | GILD | Restricted Stock Unit | Common Stock (8,530) | — | — | 8,530 | Acquired |
| Jan. 2, 2025 | GILD | Restricted Stock Unit | Common Stock (48,975) | — | — | 48,975 | Acquired |
| Feb. 6, 2019 | ATRA | Employee Stock Option (Right to Buy) | Common Stock (50,000) | $38.47 | Feb. 5, 2029 | 50,000 | Acquired |
| May 7, 2018 | ATRA | Employee Stock Option (Right to Buy) | Common Stock (85,000) | $42.05 | May 6, 2025 | 85,000 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Initial ownership (Form 3) 1 holding
Securities held when first becoming an insider, per SEC Form 3.
| Date | Ticker | Security | Shares | Ownership |
|---|---|---|---|---|
| Feb. 10, 2025 | RCUS | Common Stock | 0 | Direct |
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
GILD
M.D., Ph.D. Chief Medical Officer| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2025 | $969,231 | $3,000,000 | $6,999,758 | $1,000,043 | $1,603,594 | — | $350,252 | $13,922,878 |
| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2019 | $246,104 | — | — | $1,331,985 | — | — | $137,773 | $3,245,062 |
| 2018 | $320,385 | $427,767 | — | — | — | — | $451 | $4,972,439 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.